Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more
Lixte Biotechnology Holdings Inc (LIXT) - Total Assets
Latest total assets as of September 2025: $5.43 Million USD
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXT) holds total assets worth $5.43 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lixte Biotechnology Holdings Inc - Total Assets Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lixte Biotechnology Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lixte Biotechnology Holdings Inc's total assets of $5.43 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lixte Biotechnology Holdings Inc's current assets represent 90.7% of total assets in 2024, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 90.7% of total assets in 2024, down from 100.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lixte Biotechnology Holdings Inc Competitors by Total Assets
Key competitors of Lixte Biotechnology Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lixte Biotechnology Holdings Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lixte Biotechnology Holdings Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lixte Biotechnology Holdings Inc is currently not profitable relative to its asset base.
Lixte Biotechnology Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.42 | 5.13 | 24.15 |
| Quick Ratio | 10.42 | 5.13 | 24.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.91 Million | $ 1.36 Million | $ 5.01 Million |
Lixte Biotechnology Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Lixte Biotechnology Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.66 |
| Latest Market Cap to Assets Ratio | 14.97 |
| Asset Growth Rate (YoY) | -73.4% |
| Total Assets | $1.15 Million |
| Market Capitalization | $17.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lixte Biotechnology Holdings Inc's assets at a significant premium ( 14.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lixte Biotechnology Holdings Inc's assets decreased by 73.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lixte Biotechnology Holdings Inc (2005–2024)
The table below shows the annual total assets of Lixte Biotechnology Holdings Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.15 Million | -73.41% |
| 2023-12-31 | $4.31 Million | -22.51% |
| 2022-12-31 | $5.56 Million | +9.16% |
| 2021-12-31 | $5.09 Million | -2.59% |
| 2020-12-31 | $5.23 Million | +95.67% |
| 2019-12-31 | $2.67 Million | -38.39% |
| 2018-12-31 | $4.34 Million | +217.00% |
| 2017-12-31 | $1.37 Million | +215.65% |
| 2016-12-31 | $433.41K | -27.52% |
| 2015-12-31 | $597.98K | +10.88% |
| 2014-12-31 | $539.30K | -3.36% |
| 2013-12-31 | $558.04K | -68.17% |
| 2012-12-31 | $1.75 Million | +307.90% |
| 2011-12-31 | $429.77K | -77.75% |
| 2010-12-31 | $1.93 Million | +20.61% |
| 2009-12-31 | $1.60 Million | +3000.20% |
| 2008-12-31 | $51.65K | -91.79% |
| 2007-12-31 | $629.11K | -16.24% |
| 2006-12-31 | $751.07K | +16118.25% |
| 2005-12-31 | $4.63K | -- |